Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689
- Study type
- Other
- Design
- Perspective/commentary article (apparently a note or letter) on the KEYNOTE-689 trial; the PubMed record does not specify the exact article type.
- Source
- J Clin Oncol · 2026
In plain words
This article is an expert note from a group of doctors about immunotherapy given before and after surgery for squamous cell cancer of the head and neck. Going by the title, the authors question how much real benefit this approach gives after the results of the KEYNOTE-689 trial. This record has no further details; discuss any treatment decision with your own doctor.
Study population
The PubMed record has no abstract and no information on the study population. Based on the title, the article concerns patients with resectable head and neck squamous cell carcinoma.
Endpoints
The PubMed record has no abstract; therefore no endpoints are reported.
Safety and side effects
No information is available in the PubMed record.
Clinical significance and place in guidelines
The PubMed record has no abstract, and no firm conclusion can be drawn about its impact on clinical practice or guideline recommendations. The title indicates that the authors are sceptical about the clinical benefit of perioperative immunotherapy in these patients. Regulatory approvals and clinical guidelines should be checked separately.
Limitations
This card was prepared only from the bibliographic information and the title of the article, as the abstract was not available in the record. The full text of the article must be reviewed to evaluate the authors' arguments.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.